Natera (NTRA) has moved into focus after a favorable patent ruling against ArcherDx and Invitae, royalty income tied to MRD products, broad uptake of its Signatera test, and recent progress toward ...
Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies.Austin, United States, April 13, 2026 (GLOBE NEWSWIRE) -- As per the SNS ...
This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results